Vedolizumab
MLN0002-3026
Phase 3 small_molecule completed
Quick answer
Vedolizumab for Colitis, Ulcerative is a Phase 3 program (small_molecule) at Takeda with 5 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Colitis, Ulcerative
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed